The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $61.32

Today's change-0.30 -0.49%
Updated July 28 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Spdr S&P Biotech Etf

NYSE: XBI
Last

(U.S.) $61.32

Today's change-0.30 -0.49%
Updated July 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Reversal following new 100-day high

Spdr S&P Biotech Etf closed lower Thursday, dropping (U.S.)$0.30 or 0.49% to (U.S.)$61.32 after setting a new 100-day high. Over the last five days, shares have gained 4.11%, but are down 12.65% for the last year to date. Shares have underperformed the S&P 500 by 32.63% during the last year.

Key company metrics

  • Open(U.S.) $61.65
  • Previous close(U.S.) $61.62
  • High(U.S.) $62.05
  • Low(U.S.) $60.60
  • Bid / Ask-- / --
  • YTD % change-12.65%
  • Volume8,982,296
  • Average volume (10-day)6,288,468
  • Average volume (1-month)7,470,252
  • Average volume (3-month)7,347,677
  • 52-week range(U.S.) $44.16 to (U.S.) $87.15
  • Beta1.43
  • Trailing P/E3.36×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.45
  • Dividend yield0.73%
  • Trailing EPS(U.S.) $18.23
Updated July 28 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,202.84%

Based on its net profit margin of 2,202.84%, Spdr S&P Biotech Etf is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

Latest Press Releases

    No Press Release Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q4/2014Q2/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Jun 30, 201406/30/2014Dec 31, 201312/31/2013Jun 30, 201306/30/2013
Revenue81032
Total other revenue--------
Total revenue81032
Gross profit--------
Total cost of revenue--------
Total operating expense2221
Selling / general / administrative2221
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income6811
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax262141200125
Income after tax262141200125
Income tax, total--000
Net income262141200125
Total adjustments to net income--------
Net income before extra. items262141200125
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items262141200125
Inc. avail. to common incl. extra. items262141200125
Diluted net income262141200125
Dilution adjustment--------
Diluted weighted average shares23202327
Diluted EPS excluding extraordinary itemsvalue per share11.217.028.674.61
Dividends per sharevalue per share0.350.310.040.03
Diluted normalized EPSvalue per share11.217.028.674.61